ISO 9001:2015 Certified Company
CloseClose the Loader
The USFDA’s 2024 regulatory changes At Vigilare Biopharma, we understand the complexities and challenges that pharmaceutical companies face when navigating the ever-evolving regulatory landscape. The USFDA’s 2024 regulatory changes reflect a significant shift towards enhancing drug safety, efficacy, and accessibility. […]
Here are the top 10 trends in pharmaceutical industry innovations to embrace in 2024 1. Rise in Pharmacovigilance Market: The pharmacovigilance market is expected to grow at a CAGR of 13.6% from 2021 to 2028. Pharmacovigilance is the science of […]
At Vigilare Biopharma We strongly believe that medications play a crucial role in modern healthcare, but their benefits are intricately linked to their safety. A robust pharmacovigilance system is vital to ensure that medications are used safely and effectively. This […]
The cosmetic facility that manufactures or processes a cosmetic product for distribution in the United States on December 29, 2022, must register each facility before July 1, 2024. Cosmetic facilities that first engage in the manufacturing or processing of a cosmetic product for distribution in the United States after December 29, 2022, must register within 60 days of first engaging in such activity or by July 1, 2024, whichever is later.
Pharmacovigilance is the science and practice of monitoring, evaluating, and managing the safety of medicinal products. It is essential to ensure that the benefits of a product outweigh its risks, and to identify and prevent any adverse effects or interactions […]
Pharmacovigilance guidelines serve as essential frameworks and standards that govern the practice of pharmacovigilance globally. These guidelines provide guidance and recommendations for various stakeholders involved in drug safety monitoring, including regulatory authorities, pharmaceutical companies, healthcare professionals, and researchers. Here is […]
